Journal Mobile Options
Table of Contents
Vol. 44, No. 2, 2001
Issue release date: August 2001
Neuropsychobiology 2001;44:95–98
(DOI:10.1159/000054924)

Association between the Ser9Gly Polymorphism of the Dopamine D3 Receptor Gene and Tardive Dyskinesia in Chinese Schizophrenic Patients

Liao D.-L. · Yeh Y.-C. · Chen H.-M. · Chen H. · Hong C.-J. · Tsai S.-J.
aDepartment of Psychiatry, Executive Yuan Department of Health, Pali Psychiatric Hospital, bDepartment of Psychiatry, Veterans General Hospital-Taipei, cDivision of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

It has been suggested that dopamine D3 receptor (DRD3) may have important implications for antipsychotic-induced tardive dyskinesia (TD). Previous studies have demonstrated an association between a serine to glycine polymorphism in the first exon of the DRD3 gene and TD; however, the results have been inconsistent. Therefore, we have replicated these studies using a Chinese sample population. A total of 115 schizophrenic patients from chronic wards were assessed for TD severity using the Abnormal Involuntary Movements Scale (AIMS) and were subsequently genotyped for the DRD3 polymorphism. The mean AIMS score for patients carrying the heterozygote (DRD3ser-gly) was significantly greater than for those with the homozygotes (DRD3ser-ser and DRD3gly-gly). Our results are in line with a previous report, the results of which suggest that the presence of the DRD3ser-gly genotype may be a risk factor for the development of TD in patients treated with antipsychotics.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kane JM, Smith JM: Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473–481.
  2. Yassa R, Ananth J: Familial tardive dyskinesia. Am J Psychiatry 1981;138:1618–1619.
  3. O’Callaghan E, Larkin C, Kinsella A, Waddington JL: Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia. Br J Psychiatry 1990;157:578–584.
  4. Jeste DV, Wyatt RJ: Dogma disputed: Is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity? J Clin Psychiatry 1981;42:455–457.

    External Resources

  5. Chen CH, Wei FC, Koong FJ, Hsiao KJ: Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827–829.
  6. Inada T, Dobashi I, Sugita T, Inagaki A, Kitao Y, Matsuda G, Kato S, Takano T, Yagi G, Asai M: Search for a susceptibility locus to tardive dyskinesia. Hum Psychopharmacol 1997;12:35–39.

    External Resources

  7. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G: D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 1998;779:58–74.

    External Resources

  8. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Jonsson E, Sedvall G, Schwartz JC: Amino acid substitution in the dopamine D3 receptors a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992;2:249–256.
  9. Segman RH, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B: Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247–253.

    External Resources

  10. Gaitonde EJ, Morris A, Sivagnanasundaram S, McKenna PJ, Hunt DM, Mollon JD: Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: Analysis of symptom ratings, family history, age at onset, and movement disorders. Am J Med Genet 1996;67:455–458.
  11. Rietschel M, Krauss H, Muller DJ, Schulze TG, Knapp M, Marwinski K, Maroldt AO, Paus S, Grunhage F, Propping P, Maier W, Held T, Nothen MM: Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000;250:31–35.

    External Resources

  12. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL: Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999;21:17–27.

    External Resources

  13. Steen VM, Lovlie R, MacEwan T, McCreadie RG: Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139–145.

    External Resources

  14. Guy W: Early Clinical Drug Evaluation Unit. Assessment Manual for Psychopharmacology. Washington, Department of Health Education and Welfare, 1976.
  15. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K: Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998;32:107–113.
  16. Schwartz JC, Diaz J, Pilon C, Sokoloff P: Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000;31:277–287.

    External Resources

  17. Lundstrom K, Turpin MP: Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996;225:1068–1072.
  18. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC: Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 1992;29:858–860.
  19. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B: Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000;152:408–413.

    External Resources

  20. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S: Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101–106.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00